Our Mission

To transform the lives of patients with T cell deficiencies who are at risk for, or suffering from, devastating and life-threatening viral infections and diseases.

Restoring Immunity

Our approach involves the restoration of viral immunity through the adoptive transfer of allogeneic, off-the-shelf virus-specific T cell (VST) therapy candidates, which have been prospectively generated from healthy, eligible donors. These cells are immediately available for patients at risk from the life-threatening consequences of viral diseases due to T cell deficiencies.
Our Platform
Our proprietary platform develops VST therapy candidates designed to restore immunity in patients with T cell deficiencies.
learn

The Global Leader

Our allogeneic, off-the-shelf VSTs are designed to treat or prevent devastating viral diseases in patients with T cell deficiencies who have limited or no treatment options.
Our Pipeline
Our investigational allogeneic, off-the-shelf VST therapy candidates target 12 different devastating viruses to treat or prevent life-threatening viral diseases.
VIEW
Life @AlloVir
Our founders have a singular vision: to create VST therapy candidates that serve patients at risk of the devastating consequences of severe viral diseases.
EXPLORE

Collective Experience

Our team has more than 20 years of clinical experience with VSTs, progressing products from early stage discovery to clinical trials, regulatory approval and commercialization.

Baylor College of Medicine

Our technology platform was developed by world-class scientists at the Baylor College of Medicine’s Center for Cell and Gene Therapy. We continue to collaborate on basic and translational research of novel cell therapies through sponsored research agreements. This collaboration with the Center for Cell and Gene Therapy has enabled us to translate our research into clinical protocols at Texas Children’s Hospital and Houston Methodist Hospital in pediatric and adult patients, respectively.

ElevateBio BaseCamp

An affiliate of ElevateBio, AlloVir has access to the clinical, manufacturing, and commercial expertise of ElevateBio BaseCamp, a centralized cell and gene therapy manufacturing facility and innovation hub.

AlloVir is the Global Leader in Developing VST Immunotherapies

We develop highly innovative allogeneic, off-the-shelf VST therapy candidates designed to treat or prevent devastating viral infections and diseases.

Our Pipeline

Our allogeneic, off-the-shelf, VST therapy candidates target 12 different devastating viruses to treat or prevent life-threatening viral diseases.
view

Our Platform

Our proprietary platform develops allogeneic, off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies.
learn

Our People

Our founders have a singular vision: to serve patients at risk of the devastating consequences of severe viral infections and diseases.
meet